BPC-157
A synthetic 15-amino acid pentadecapeptide derived from a partial sequence of the Body Protection Compound — a cytoprotective protein isolated from human gastric juice. BPC-157 exhibits no sequence homology with other known gastric peptides and demonstrates pleiotropic tissue-protective and regenerative activity across gastrointestinal, musculoskeletal, neurological, and vascular systems in over 30 years of preclinical research.
01 Mechanism of Action
BPC-157's pharmacological profile is characterised by pleiotropic cytoprotective and organoprotective activity — meaning it appears to confer protective and regenerative effects across multiple organ systems through a network of interacting molecular pathways rather than through a single receptor-ligand interaction. This breadth of activity, while compelling in preclinical data, is also a source of ongoing mechanistic uncertainty.
The compound is native and stable in human gastric juice for more than 24 hours — a property that distinguishes it from most endogenous peptides and supports its original characterisation as a cytoprotective mediator within the gastrointestinal mucosal defence system. This gastric juice stability also underpins research into oral bioavailability, which has been demonstrated in rodent models.
02 Research Applications & Evidence Base
BPC-157's published research history spans more than 30 years and over 500 indexed publications, the majority from preclinical rodent models. This represents the broadest preclinical evidence base of any peptide in the Peplix catalog. The following application areas reflect published literature and are presented for research reference only.
-
Musculoskeletal Injury & Repair
The most extensively studied application domain. Preclinical models have documented accelerated healing in tendon ruptures, ligament tears, muscle detachment injuries, and bone fractures — including non-union (pseudoarthrosis) models where conventional healing is impaired. A 2025 systematic review (PMC12313605) identified 36 studies from 1993–2024, all showing structural, functional, and biomechanical improvements in musculoskeletal injury models. One human clinical study reported that 7 of 12 subjects with chronic knee pain experienced sustained relief for over six months following a single BPC-157 intra-articular injection.
-
Gastrointestinal Mucosal Protection
BPC-157's origin as a gastric peptide underpins its most established research area. Studies demonstrate protective and healing effects against gastric and duodenal ulcers, inflammatory bowel disease models, and chemically induced GI injury (ethanol, NSAID, cysteamine). Gastroprotective activity has been demonstrated across multiple administration routes — systemic, oral, and direct mucosal — with active doses in the ng/kg to µg/kg range, orders of magnitude lower than most pharmacological agents.
-
Neuroprotection & CNS Research
Animal models of traumatic brain injury, spinal cord compression, and peripheral nerve transection have shown BPC-157-associated improvements in motor function recovery and neural tissue preservation. Dopaminergic and serotonergic pathway interactions have been documented in models of Parkinson's disease, depression, and addiction. BPC-157 has also been studied in the context of interstitial cystitis, a condition with a significant neuroinflammatory component, where its anti-inflammatory and epithelial restoration properties are relevant.
-
Vascular & Cardiac Research
BPC-157 modulates blood pressure, counteracts cardiac arrhythmias following reoxygenation injury, and protects endothelial integrity in models of ischaemia-reperfusion damage. Its interaction with the NO system underpins these cardiovascular effects. Portal hypertension and liver cirrhosis models have also been investigated, with BPC-157 demonstrating reversal of liver lesions and normalisation of portal pressure in chronically alcohol-dosed rodents.
-
Ocular & Corneal Research
A distinctive finding in the BPC-157 literature is corneal ulcer healing accompanied by maintained corneal transparency — a counter-intuitive result for a pro-angiogenic compound, as corneal healing is normally associated with neovascularisation that impairs optical clarity. BPC-157's angiogenic activity appears to be regulated rather than constitutive, permitting healing while preserving corneal avascular privilege. Retinal ischaemia and glaucoma models have also been investigated.
Evidence Strength by Research Area
Human Clinical Data — Summary
| Study | Population / Intervention | Outcome | Status |
|---|---|---|---|
| Lee & Burgess, 2025 | 2 healthy adults; IV infusion up to 20 mg | No adverse cardiac, hepatic, renal, thyroid, or metabolic effects; well-tolerated; plasma clearance within 24h | Pilot safety study |
| Knee injection case series | 12 subjects; chronic knee pain; single intra-articular injection | 7/12 subjects reported sustained pain relief >6 months | Uncontrolled; no placebo arm |
| Interstitial cystitis | Preclinical model; BPC-157 vs anti-inflammatory controls | Anti-inflammatory & epithelial restoration effects observed | Animal model only |
Human clinical data for BPC-157 is extremely limited as of 2025. The 2025 IV pilot study represents the first formal pharmacokinetic and safety assessment in humans.
03 Observed Research Effects
The following effects are drawn from published preclinical and the limited available clinical literature. BPC-157's unusually broad effect profile across organ systems is one of its most distinctive — and mechanistically puzzling — characteristics.
Documented Preclinical Effects
Safety Profile & Research Caveats
BPC-157's safety profile across preclinical models is notably favourable — LD1 (the dose at which 1% of test animals die) has not been achieved in any published toxicology study, and no dose-limiting toxicity has been established in rodent models. The 2025 human pilot study (Lee & Burgess) at doses up to 20 mg IV showed no clinically meaningful adverse findings. However, significant research gaps and contextual caveats apply:
- Angiogenesis and oncological concerns — BPC-157 promotes angiogenesis via VEGFR2 activation. While its tissue-specific angiogenic profile appears distinct from pathological tumour vascularisation (evidenced by corneal healing without neovascularisation), the theoretical risk of promoting growth in pre-existing occult tumours has not been ruled out. The 2025 MDPI review (Sikiric et al.) argues BPC-157 angiogenesis does not follow Folkman's classical tumour angiogenesis model, but independent confirmation of oncological safety is absent. Any research design involving tumour-bearing animal models should account for this uncertainty.
- Absence of large-scale human trials — With fewer than 20 total human subjects exposed to synthetic BPC-157 in any formal study context, the human safety and pharmacokinetic profile is almost entirely extrapolated from animal data. The 2025 pilot study (n=2) is the only published pharmacokinetic characterisation in humans.
- Single-lab concentration (Sikiric group, Zagreb) — The overwhelming majority of BPC-157 preclinical research originates from one academic group at the University of Zagreb. While this research is prolific, thorough, and internally consistent, independent replication in external laboratories is sparse. Researchers should account for this publication concentration when interpreting effect sizes and generalisability.
- Short plasma half-life — Following IM or IV administration, BPC-157 is rapidly cleared from circulation (half-life <30 minutes in plasma; baseline within 24h at 20 mg IV per the 2025 pilot). In vitro studies should be designed with this rapid clearance in mind. Oral route stability in human gastric juice is excellent (>24h), but oral bioavailability in humans has not been formally established.
- FDA Category 2 classification (2023) — The FDA has classified BPC-157 as a Category 2 bulk drug substance for compounding purposes, citing insufficient evidence regarding human safety. This classification does not restrict research use but signals the regulatory context. WADA listed BPC-157 as a prohibited substance in 2022 under Category S0 (non-approved substances); it is no longer on the current prohibited list as of the most recent revision.
04 Chemical & Physical Profile
05 Reconstitution Reference
BPC-157 is freely soluble in water and reconstitutes readily. The following concentrations reflect those used in published preclinical research protocols. All calculations assume a 5 mg lyophilized vial.
| Bacteriostatic Water Added | Resulting Concentration | Volume per 10 µg dose | Volume per 250 µg dose |
|---|---|---|---|
| 1.0 mL | 5,000 µg/mL (5 mg/mL) | 0.002 mL (2 µL) | 0.05 mL (50 µL) |
| 2.0 mL | 2,500 µg/mL (2.5 mg/mL) | 0.004 mL (4 µL) | 0.10 mL (100 µL) |
| 5.0 mL | 1,000 µg/mL (1.0 mg/mL) | 0.01 mL (10 µL) | 0.25 mL (250 µL) |
| 10.0 mL | 500 µg/mL (0.5 mg/mL) | 0.02 mL (20 µL) | 0.50 mL (500 µL) |
Note: BPC-157 preclinical studies commonly employ doses in the 10 ng/kg to 10 µg/kg body weight range administered once or twice daily. At these very low doses, accurate dilution and measurement is essential — working stock solutions should be prepared accordingly.
06 Research Literature
A selection of key publications spanning BPC-157's research history from 1992 to 2025. With over 500 indexed publications, the literature is extensive — the references below represent mechanistically foundational and most-cited works alongside recent systematic reviews.
Order BPC-157 · 5 mg Vial
≥99.0% HPLC purity · CoA from Freedom Diagnostics · Cold shipped · Lot 2603